Trial Profile
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Durvalumab (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- Acronyms EMERALD-Y90
- Sponsors AstraZeneca
- 06 Mar 2024 Status changed from not yet recruiting to recruiting.
- 05 Jan 2024 Planned initiation date changed from 30 Sep 2023 to 31 Jan 2024.
- 19 Sep 2023 New trial record